Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Briefings in Bioinformatics
|
September 29, 2016
Rare variant association test in family-based sequencing studies
Xuefeng Wang, Zhenyu Zhang, Nathan Morris, et al.
British Journal of Pharmacology
|
December 23, 2025
Cannabigerol reverses mechanical allodynia through α<sub>2A</sub>-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy
Quinn W Wade, Nathan Morris, Diana E Sepulveda, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
Dynamic neuroinflammatory profiles predict Alzheimer's disease pathology in microglia-containing cerebral organoids
Madison K Kuhn, Rachel Y Kang, ChaeMin Kim, et al.
The American Journal of Gastroenterology
|
March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
Scott D Lee, Severine Vermeire, Ryan Ungaro, et al.
Plos One
|
May 6, 2016
The Response of microRNAs to Solar UVR in Skin-Resident Melanocytes Differs between Melanoma Patients and Healthy Persons
Jingfeng Sha, Brian R Gastman, Nathan Morris, et al.
The Journal of Physiology
|
August 21, 2013
Effects of optional structural elements, including two alternative amino termini and a new splicing cassette IV, on the function of the sodium-bicarbonate cotransporter NBCn1 (SLC4A7)
Ying Liu, Xue Qin, Deng-Ke Wang, et al.
Journal of Crohn'S & Colitis
|
April 14, 2023
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Fernando Magro, Rish K Pai, Taku Kobayashi, et al.
Cell
|
March 14, 2015
Codon optimality is a major determinant of mRNA stability
Vladimir Presnyak, Najwa Alhusaini, Ying-Hsin Chen, et al.
Journal of Crohn'S & Colitis
|
June 13, 2024
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme
Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, et al.
Crohn'S & Colitis 360
|
November 30, 2023
Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
Bruce E Sands, Brian G Feagan, Theresa Hunter Gibble, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Briefings in Bioinformatics
|
September 29, 2016
Rare variant association test in family-based sequencing studies
Xuefeng Wang, Zhenyu Zhang, Nathan Morris, et al.
British Journal of Pharmacology
|
December 23, 2025
Cannabigerol reverses mechanical allodynia through α<sub>2A</sub>-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy
Quinn W Wade, Nathan Morris, Diana E Sepulveda, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
Dynamic neuroinflammatory profiles predict Alzheimer's disease pathology in microglia-containing cerebral organoids
Madison K Kuhn, Rachel Y Kang, ChaeMin Kim, et al.
The American Journal of Gastroenterology
|
March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
Scott D Lee, Severine Vermeire, Ryan Ungaro, et al.
Plos One
|
May 6, 2016
The Response of microRNAs to Solar UVR in Skin-Resident Melanocytes Differs between Melanoma Patients and Healthy Persons
Jingfeng Sha, Brian R Gastman, Nathan Morris, et al.
The Journal of Physiology
|
August 21, 2013
Effects of optional structural elements, including two alternative amino termini and a new splicing cassette IV, on the function of the sodium-bicarbonate cotransporter NBCn1 (SLC4A7)
Ying Liu, Xue Qin, Deng-Ke Wang, et al.
Journal of Crohn'S & Colitis
|
April 14, 2023
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Fernando Magro, Rish K Pai, Taku Kobayashi, et al.
Cell
|
March 14, 2015
Codon optimality is a major determinant of mRNA stability
Vladimir Presnyak, Najwa Alhusaini, Ying-Hsin Chen, et al.
Journal of Crohn'S & Colitis
|
June 13, 2024
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme
Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, et al.
Crohn'S & Colitis 360
|
November 30, 2023
Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
Bruce E Sands, Brian G Feagan, Theresa Hunter Gibble, et al.
Page
of 6